Aptamer reports decent technical, commercial progress
![Aptamer Group | Sharecast graphic / Josh White dl aptamer group plc aim health care healthcare pharmaceuticals and biotechnology logo 20230505 1546](https://img2.s3wfg.com/web/img/images_uploaded/9/5/dl-aptamer-group-plc-aim-health-care-healthcare-pharmaceuticals-and-biotechnology-logo-20230505-1546_620x350.jpg)
Aptamer Group
0.26p
16:45 26/07/24
-13.33%
-0.04p
Aptamer Group reported solid progress on both the technical and commercial fronts on Friday as it held its annual general meeting.
FTSE AIM All-Share
778.91
16:25 26/07/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,767.31
16:45 26/07/24
1.27%
284.71
The AIM-traded firm said that since its recapitalisation in August, it had undergone a cost reduction initiative, streamlining production processes to boost capacity, and decreased material requirements from customers.
It also continued to expand and convert its commercial pipeline, with a recent partnership involving a genetic medicines company to advance Optimer development, facilitating targeted delivery of new medicines.
At 1121 GMT, shares in Aptamer Group were down 2.5% at 1.17p.
Reporting by Josh White for Sharecast.com.